Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 23 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Zagouri, Flora [Clear All Filters]
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer..
Clin Breast Cancer. 14(5), 330-8.
(2014).
(2016).
(2018).
Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016).
(2015). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017).
(2015).
(2016).
Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?.
Cancer Immunol Immunother.
(2020). Protein expression patterns of cell cycle regulators in operable breast cancer..
PLoS One. 12(8), e0180489.
(2017). The Role of CXCL13 and CXCL9 in Early Breast Cancer..
Clin Breast Cancer. 20(1), e36-e53.
(2020).
(2015).
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting..
Oncotarget. 7(22), 32731-53.
(2016). Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes..
PLoS One. 11(9), e0163138.
(2016). Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer..
Cancer Genomics Proteomics. 17(2), 181-193.
(2020).
(2016).